GENE ONLINE|News &
Opinion
Blog

2020-05-29| Technology

What to Expect from the ASCO20 Virtual Program

by GeneOnline
Share To

Photo Courtesy: ASCO

Taking the COVID-19 pandemic into consideration, last March, the organizers of the American Society of Clinical Oncology (ASCO), decided to convert their highly regarded annual meeting into a virtual format. Originally scheduled to take place in Chicago for 5 days, the conference will now transpire as an online program between May 29 – 31. Here is a brief preview of what to expect from the event.

The ASCO annual meeting is more than just a scientific congregation of physicians, researchers, and industry professionals reporting on the latest advances in cancer research. It is also an opportunity for education and patient advocacy. While a virtual program may not be an ideal replacement for the in-person meeting to achieve its full potential, the decision is the right one, considering the circumstances. Besides, it offers access to a horde of participants around the globe, who might have otherwise skipped the event. We attempted to give a glimpse of what to look forward to at the conference.

 
Anticipated Clinical Trial Results

In their official website, ASCO announced some of the top studies to be presented at the meeting. They include:

Plenary Session
Other Sessions
 
Select Company Presentations
  1. The use of tumor mutational burden (TMB) as a pan-tumor genomic biomarker across a variety of cancers
  2. FMI and Flatiron Health’s clinico-genomic database demonstrating that the combination of TMB and PD-L1 can better predict immunotherapy response in lung cancer patients (TPS2087)

 

References
  1. https://meetings.asco.org/am/virtual-program

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Roche’s Polivy Wins Support From FDA Adcom For Treating B-Cell Cancer
2023-03-10
Genentech Takes Biogen to Court Over Stockpiled Multiple Sclerosis Drug Royalties
2023-03-01
LATEST
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
2023-03-28
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
2023-03-28
Vertex and CRISPR Collaborate Again with $330 Million Diabetes Gene Editing Deal
2023-03-28
Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC
2023-03-28
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
2023-03-27
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Scroll to Top